Bain Capital Life Sciences led a $100m Series C funding round in JenaValve.

Bain Capital Life Sciences, a private equity firm, led a $100m Series C funding round in JenaValve, a clinical-stage medical device company, with participation from Andera Partners, Valiance Advisors, Gimv, Cormorant Asset Managers, Pictet Alternative Advisors, Qatar Investment Authority and Innovatus Capital Partners. “JenaValve is committed to becoming the first and only FDA-approved transfemoral transcatheter valve system indicated for symptomatic, severe aortic regurgitation, addressing an estimated multi-billion-dollar U.S. market opportunity. This financing provides sufficient capital for us to conclude our ALIGN-AR clinical trial and prepare for a commercial launch in the US,” John Kilcoyne, JenaValve CEO.